New drug aims to slash Sky-High cholesterol in rare genetic disease
NCT ID NCT06712771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests VSA003, an RNAi drug that targets a protein called ANGPTL3, in 46 Chinese adolescents and adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing extremely high cholesterol. Participants receive either VSA003 or a placebo injection, and researchers measure how much their LDL cholesterol drops after 6 months. The goal is to see if this drug can safely lower cholesterol and reduce heart disease risk in this hard-to-treat population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VSA003 (also called AROANG3 or Zodasiran), an RNAi drug targeting ANGPTL3
What this could lead to
If successful, this could provide a new treatment option to lower dangerously high cholesterol in people with HoFH, potentially reducing their risk of heart disease.
What could go wrong
This is a small, early-phase 3 trial with only 46 participants, so results may not apply to everyone. The drug is still experimental, and its long-term safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China